State Street’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$183K Sell
13,934
-40,917
-75% -$914K ﹤0.01% 3927
2026
Q1
$1.44M Sell
54,851
-61,536
-53% -$7.74M ﹤0.01% 3396
2025
Q4
$28.9M Buy
116,387
+67,841
+140% +$15.5M ﹤0.01% 2052
2025
Q3
$10.2M Buy
48,546
+17,528
+57% +$3.09M ﹤0.01% 2632
2025
Q2
$3.05M Buy
31,018
+19,985
+181% +$1.74M ﹤0.01% 3156
2025
Q1
$971K Buy
11,033
+1,427
+15% +$132K ﹤0.01% 3432
2024
Q4
$695K Buy
9,606
+696
+8% +$47.7K ﹤0.01% 3557
2024
Q3
$703K Hold
8,910
– – ﹤0.01% 3534
2024
Q2
$642K Buy
8,910
+294
+3% +$17.6K ﹤0.01% 3536
2024
Q1
$813K Sell
8,616
-303
-3% -$26.7K ﹤0.01% 3519
2023
Q4
$651K Buy
8,919
+4,792
+116% +$283K ﹤0.01% 3582
2023
Q3
$275K Sell
4,127
-182
-4% -$16.8K ﹤0.01% 3842
2023
Q2
$414K Sell
4,309
-12,235
-74% -$1.22M ﹤0.01% 3740
2023
Q1
$1.67M Sell
16,544
-331,506
-95% -$50.8M ﹤0.01% 3394
2022
Q4
$60.4M Buy
348,050
+300,826
+637% +$198M ﹤0.01% 1503
2022
Q3
$45.3M Sell
47,224
-1,216
-3% -$1.21M ﹤0.01% 1653
2022
Q2
$32.4M Buy
48,440
+7,091
+17% +$4.4M ﹤0.01% 1918
2022
Q1
$28.7M Buy
41,349
+198
+0.5% +$153K ﹤0.01% 2139
2021
Q4
$37.2M Buy
41,151
+7,866
+24% +$7.47M ﹤0.01% 2020
2021
Q3
$33.5M Sell
33,285
-8,311
-20% -$6.12M ﹤0.01% 2103
2021
Q2
$27M Sell
41,596
-6,725
-14% -$4.66M ﹤0.01% 2318
2021
Q1
$35.8M Buy
48,321
+14,185
+42% +$11.4M ﹤0.01% 1984
2020
Q4
$26.4M Buy
34,136
+7,199
+27% +$5.67M ﹤0.01% 2066
2020
Q3
$26.7M Buy
26,937
+3,180
+13% +$3.37M ﹤0.01% 1865
2020
Q2
$24.7M Buy
23,757
+3,021
+15% +$3.04M ﹤0.01% 1920
2020
Q1
$16.8M Buy
20,736
+170
+0.8% +$178K ﹤0.01% 1949
2019
Q4
$25.7M Buy
20,566
+11,217
+120% +$18.1M ﹤0.01% 1965
2019
Q3
$12.6M Buy
9,349
+5,006
+115% +$7.96M ﹤0.01% 2348
2019
Q2
$7.71M Buy
4,343
+2,434
+128% +$3.73M ﹤0.01% 2610
2019
Q1
$3.31M Buy
+1,909
New +$3.18M ﹤0.01% 2946

Other funds holding GOSS

State Street's GOSS Position: Q2 2026 in Review

State Street reduced its Gossamer Bio (GOSS) stake by 75% in Q2 2026, selling an estimated $914K and leaving 13,934 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #3927.

State Street first reported a position in GOSS in Q1 2019 and has held it in 30 quarters since. The position peaked at $60.4M in Q4 2022. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • State Street held 13,934 shares of Gossamer Bio worth $183K as of Q2 2026.
  • State Street sold 40,917 Gossamer Bio shares in Q2 2026, an estimated $914K.
  • Gossamer Bio made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3927 holding.
  • State Street first reported a position in Gossamer Bio in Q1 2019 and has held it in 30 quarters since.
  • State Street's Gossamer Bio position peaked at $60.4M in Q4 2022.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.